Abstract The cancer stem cell hypothesis suggests that a subpopulation of tumor cells exhibits stem cell properties such as self-renewal capacity and multilineage differentiation. The modern day cancer stem cell model emerged following initial work in leukemia and subsequent identification of putative cancer stem cell populations in a variety of solid tumors. These studies have been largely based on transplantation assays in immunodeficient mice and have revolutionized how we view tumor cell heterogeneity. However, recent studies with both genetically engineered and more highly immunocompromised animal models have challenged the notion that cancer stem cells are a rare subpopulation. Issues with the cell surface markers used to enrich for cancer stem cells and the hierarchical organization within tumors have also come to light and remain unresolved. As we continue to optimize in vivo models and understand microenvironmental influences, our view of cancer stem cells within heterogeneous tumors will likely become even more complex.
Introduction
Current cancer stem cell (CSC) theory posits that tumors contain cell subpopulations that exhibit stem cell features such as self-renewal capacity and multilineage differentiation [1] [2] [3] . These CSCs or tumor-propagating cells (TPCs) would ultimately drive tumorigenesis and must, therefore, be specifically targeted to abrogate malignant progression. While the idea of a CSC dates back several decades (See Dick [4] for a comprehensive historical overview of CSC theory), the modern day CSC model emerged following extensive studies in leukemia demonstrating that only a rare cell population could initiate tumorigenesis when transplanted into immunodeficient mice [5, 6] . This tumorinitiating capacity could be enriched by cell sorting based on CD34?/CD38-cell surface marker expression [5, 6] . Following the initial work in acute myelogenous leukemia (AML), a large number of studies have since been published on CSCs or TPCs in solid tumors including breast [7] , brain [8, 9] , colon [10, 11] , pancreatic [12] and ovarian cancers [13] [14] [15] [16] . Similar to the work with hematopoietic malignancies, these studies also utilized non-obese diabetic severe combined immunodeficient (NOD/SCID) mice to demonstrate that the tumor-initiating capacity was restricted to a rare cell subpopulation defined by specific cell surface markers.
Since these initial seminal studies were published, the CSC model has generated a lot of controversy with regards to the cell of origin, frequency of tumor initiating cells and the markers used to enrich for putative CSC subpopulations. For example, using genetically engineered mouse (GEM) models and thus immunocompetent systems, some research groups have demonstrated that transplanting as few as 10 cells is sufficient to generate a tumor in wildtype recipient mice [17 •• ] . In these mouse models of B cell and T cell lymphoma and AML, tumor initiation does not seem to be driven by rare CSC subpopulations. Moreover, recent studies using even more immunocompromised animal models such as NOD/SCID mice lacking the interleukin-2 gamma receptor (NOD/SCID IL2Rc null ) demonstrated that changes in tumor microenvironment can result in a drastic increase in the number of cells capable of forming a tumor [18 •• ]. These results underscore the potential for some xenotransplantation assays to underestimate the number of cells with CSC or tumor-initiating cell capacity.
To date, the discrepancies between different in vivo models of CSCs have yet to be resolved. This review will specifically focus on the last 5 years of CSC research, with an emphasis on the landmark animal model studies that raised further questions regarding the status of CSCs in both hematopoietic malignancies and solid tumors. Comparative results in xenograft and GEM (transgenic and knockout) animal models will be discussed. Each model will be evaluated in terms of putative CSC frequency, cell surface phenotyping and correlation with in vitro stem cell assays, as well as hierarchical arrangement of cell populations within tumors. Emerging alternative systems such xenograft zebrafish models are also examined.
Xenotransplantation Assays, GEM Models and the Frequency Issue
Xenotransplantation into immunodeficient mice has become the gold standard for evaluation of CSC properties from human tumors in vivo. Researchers have used this assay to determine the tumor initiating capacity of both unsorted and sorted fractions of human cells based on specific combinations of cell surface markers in a variety of cancers. Dissociation of primary tumors and transplantation into secondary mouse recipients enables one to evaluate self-renewal in vivo. Combined with data from limiting dilution analysis, the results for primary and secondary tumors are used to calculate a tumor-initiating cell frequency using a maximum-likelihood estimation method [19, 20] . This will determine whether a small or large subset of cells from different cancers can initiate tumor growth.
While utilization of this assay to define CSCs has led to seminal findings in cancer research, it should be emphasized that human cells in a mouse microenvironment differ from those cancer cells that grow and thrive in patients. Mouse and human tissues exhibit differences between their normal tissue stroma [21] . It is well known that the normal cell microenvironment, consisting of stromal fibroblasts, vascular networks, extracellular matrix and autologous immune cells, plays an important role in regulating tumorigenesis [22] . This includes both positive and negative effects on tumor growth and maintenance [22] . There are obviously vast differences in the immune cell function between autologous and xenogeneic systems. As putative human CSCs must be transplanted into immunocompromised mice to effectively assay tumor initiation in vivo, this has led to questions regarding the relevance of certain models in recapitulating human disease. Perhaps one of the most contentious issues among scientists studying CSCs is the frequency of this subpopulation within a tumor. Researchers have reported a wide variation in the percentage of cells that can initiate tumorigenesis using xenograft models [3] . For cancers such as melanoma, animal models like NOD/SCID mice vastly underestimate the frequency of tumorigenic cells [18 •• ]. However, it should be noted that rarity is not an obligatory feature of CSC populations. A higher cell frequency does not exclude a subpopulation from following a CSC hierarchical model. It has been suggested that these common tumorigenic cells may be part of a more ''shallow'' or limited hierarchy [3] . However, cancers such as malignant peripheral nerve sheath tumors, exhibiting a higher frequency of tumorigenic cells, have yet to be hierarchically evaluated [28] . Interestingly, melanoma has also been one of the few cancers to be reprogrammed by nuclear transfer [29] as well as by ectopic expression of Oct4, Klf4 and c-myc to the induced pluripotent stem (iPS) cell state [30] . Perhaps the incredible plasticity and adaptability of melanoma cells in various microenvironments suggests that these tumor cells may be the exception and not the rule in CSC biology.
While serial xenotransplantations assays and limiting dilution analysis are traditionally the gold standard for in vivo assessment of putative human CSC populations, these models have been plagued by a series of technical issues. Murine microenvironments and inappropriate immune responses combined with variations seen with transplantation site, recipient mouse sex and strain have prompted scientists to move towards studying CSC properties in immunocompetent, GEM models.
Kelly et al. [28] reported a range of tumorigenic cell frequencies using multiple mouse models of peripheral nerve sheath tumors. Frequency was dependent on both the genotype of the mouse model utilized and the specific assay conditions used to report tumor-initiating capacity [28] . Similarly, Tamase et al. [34] demonstrated that the tumorigenic cell population varied from about 16-50 % in individual brain tumors derived from a Ras induced p16Ink4a/p19Arf-deficient mouse model of glioblastoma combined with a GFP reporting system. However, in this model system, the authors did not distinguish between stem cells and progenitors suggesting that either or both cell types could contribute to the tumorinitiating capacity [34] . Collectively, these studies using GEM models have underscored the notion that tumors do not have to be driven by a rare CSC phenotype. In many instances, the tumorigenic cell frequency is upwards of 50 % or more. As rarity is not a prerequisite defining feature of CSCs, it is becoming increasingly acceptable for a more common cell population to be considered a CSC, tumor initiating or propagating cell.
Xenografts, GEMs and ''Markerology''
In addition to the CSC frequency disparities between xenograft models and GEMs, researchers have also seen differences in the cell surface markers used to identify and isolate CSC fractions in these model systems. Some of the best examples of these discrepancies are in breast and brain tumor models and are summarized in Table 1 . For example, using serial xenotransplantation assays in the mammary fat pad, Al-Hajj et al. [7] were the first to isolate CSCs from human breast cancers. This study, which was the first characterization of CSCs in solid tumors, isolated breast tumor stem cells based on combinatory CD44?/ CD24 low expression [7] . In contrast, murine models of breast cancer have used different cell surface markers to isolate mammary tumor stem cells [33, [36] [37] [38] [39] . Using a p53-null mammary tumor model, Zhang et al. [37] showed that a subpopulation of CD24?/CD29? cells exhibit self-renewal capacity in subsequent transplantation assays and recapitulate phenotypic properties of the primary tumor. Interestingly, a /CD24?/ CD61? selectivity enriched for highly tumorigenic stem cells in this same system. For breast cancer, there are clear discrepancies between the markers used to identify CSC populations in xenograft models and GEMs. In addition, the hierarchical organization within mammary tumors is still not well defined, and together, these issues make it difficult to assess which markers can be relied upon to reproducibly select for breast CSCs.
A similar issue with cell surface markers has been documented in malignant brain tumors. While CD133 has typically been utilized as a putative human brain tumor stem cell marker [8, 9] recent work has shown that CD133-cells display more invasive growth and aggressive behaviour than the CD133? cells typically associated with ''stem cell'' function [40, 41] . Chen et al. [41] demonstrated that a more primitive CD133-subpopulation of GBM cells gives rise to both CD133-and CD133? subsets. This was not restricted to a single tumor subtype as CD133-cells from both colon cancer [42] and brain tumors [40, [42] [43] [44] developed metastatic and highly invasive tumors respectively. This is complicated by the fact that CD133 is not exclusive to TPC populations and is also expressed in normal stem cells as well as differentiated epithelial cells in a variety of organs [45] . In fact, very little is actually known about the biological function of CD133. From a technical standpoint, antibodies currently used to isolate CSC populations recognize glycosylated epitopes that have not been fully characterized, and it has yet to be determined whether the CD133 protein or its glycosylation status is correlated with the CSC phenotype (See Bidlingmaier et al. [46] for a comprehensive overview of controversies regarding utilization of CD133 glycosylated human epitopes in defining CSCs). Interestingly, recent studies have also demonstrated that glycosylated CD133 levels are enhanced by lowering oxygen tension from 20 to 2-3 % demonstrating that CD133 function and hypoxia are linked [47] [48] [49] . While there are still several issues to be resolved, it will be necessary to break down the heterogeneity within CD133± populations to identify other markers that better select for self-renewing and possibly the most aggressive, highly invasive phenotypes.
CD133 has been used for isolation of human brain CSCs; however, in mouse models, recent studies have shown that CD15 or stage-specific embryonic antigen (SSEA1) selects for a tumorigenic cell population [50, 51] . For example, Read et al. [50] demonstrated that in a Ptc± model of medulloblastoma, the most common malignant primary pediatric brain tumor, tumors are propagated not by a stem cell-like CD133? (Prominin-1 in mice) population but by cells marked by the neuronal progenitor markers Math1 and CD15. Interestingly, CD133? cells from Ptc± mice did not form tumorspheres in vitro and were not capable of forming tumors when transplanted into the cerebellum of SCID-beige mice [50] . Ward et al. [51] also demonstrated the tumorigenic capacity of CD15? cells from Ptc± mice; however, these authors suggested that the CD15? population represents a stem cell-like and not a progenitor cell phenotype. Additional studies have lent further support to the notion that in some murine brain tumor models, including medulloblastoma [52] [53], and oligodendroglioma [54] , the cell of origin is a more restricted progenitor and not a stem cell.
Controversies surrounding brain tumor stem cell properties were further emphasized with the recent uncoupling of self-renewal in vitro from tumorigenic capacity in vivo. Using PDGF and KRAS-driven models of glioma, Barrett et al. [55] recently showed that cell populations sorted on the Inhibitor of DNA binding (ID1) protein exhibit a higher self-renewal capacity in vitro; however, these same cells demonstrate a lower tumorigenic capacity in vivo. While both ID1 high and ID1 low cells were tumorigenic in transplantation assays, these results clearly demonstrate that Barrett et al. [55] multiple lineages, including those with limited self-renewal capacity, are capable of transplanting disease [55] . Further studies that evaluate the correlation between in vivo tumorigenicity or in vitro self-renewal with patient prognosis and survival will ultimately determine which assay has greater relevance to clinical outcome.
Collectively, the differences seen between xenotransplantation assays and GEMs have several clinical implications. For example, many laboratories are working with high throughput screening technologies to identify chemical compounds that will selectively target a putative CSC or tumorigenic cell population, irrespective of whether these cells take on a more stem cell-like or progenitor phenotype. However, for these expensive screens to be valid and more importantly useful from a clinical perspective, we must be able to reproducibly select for these cell populations based on combinatory cell surface marker expression. When there are vast differences between xenograft assays and mouse models, this begs the question: What is the most reliable system for accurate prospective isolation of putative CSCs or tumor-initiating cells? While xenografts often use human cells directly isolated from patient samples, GEM technology has developed tremendously over the years, and many mouse models do recapitulate the phenotypes of their human counterparts. Ultimately, the most convincing new therapeutic targets and relevant clinical data will come from compounds that can selectively target these populations in both a xenograft and mouse model.
Xenografts, GEMs and Hierarchical Organization
While many CSC studies with GEM models have focused on the frequency controversy, more recent studies have utilized these models to address the concept of cellular hierarchies. To adhere to the CSC model, a cell population must exhibit two properties: (1) phenotypic and functional heterogeneity and (2) hierarchical organization [3] . Cellular hierarchies are defined by the tumorigenic stem cell's ability to give rise to both tumorigenic as well as nontumorigenic cells following transplantation. Using a Nf1/ p53/Pten malignant glioma mouse model combined with a nestin-DTK-IRES-GFP transgene, Chen et al. [56] recently reported that a subset of endogenous CSCs are the source of new tumor growth following ablation of proliferating cells with temozolomide. Combined treatment with ganciclovir significantly abrogated tumor progression through selective targeting of the GFP? CSC-like population. In this glioma model, tumors follow a hierarchical CSC system, and recurrence is specifically attributed to failed eradication of the CSC subpopulation [56] . This study reaffirmed the clinical relevance of putative CSCs in malignant glioblastoma.
Perhaps the most consistent and convincing evidence for a CSC hierarchical model has come from the collective studies on AML [4] . However, even within this tumor, recent studies have demonstrated variability and added to the increasing complexity of the CSC model. In NOD/ SCID mice, rare leukemic stem cells were originally shown to be exclusive to the CD34?/CD38-fraction, and only this population generated tumors in subsequent transplantation studies [5, 6] Further complicating the concept of hierarchical organization is the recent demonstration that cancer cells fractions re-establish cellular equilibrium irrespective of the cell surface markers utilized to sort subpopulations [60 •• ]. Gupta et al. [60 •• ] showed that in multiple breast cancer cell lines, the cancer stem-like fraction, as well as the more differentiated basal and luminal cell fractions formed tumors with high efficiency when co-injected with irradiated carrier cells. In response to appropriate microenvironmental cues, sorted cell fractions do not remain static and inevitably give rise to other phenotypes. We have seen similar trends in our laboratory with sorted populations from pediatric medulloblastoma cell lines [61] .
In Search of New and Improved In Vivo Models
As CSC research moves forward, we will continuously look for ways to improve existing models and optimize methods for putative CSC detection. Researchers are now working with more ''humanized'' xenograft models by coinjecting human cancer cells or sorted cancer cell populations with normal carrier cells [ This review primarily focused on murine models of CSCs; however, recent studies have proposed other systems for the study of CSC populations. For example, Barbieri et al. [63] have isolated CSC-like cells from feline mammary carcinoma. Upon injection into NOD/SCID mice, these cells generate heterogeneous tumors that recapitulate the original phenotype [63] . Cocola et al. [64] have conducted similar experiments with canine mammary carcinoma. Eguiara et al. [65] have proposed using zebrafish xenograft models as an alternative to the highly expensive mouse experiments that require more maintenance and can last upwards of several months. In particular, zebrafish embryos were utilized as a functional assay for breast cancer stem-like cell identification [65] . Zebrafish are increasingly employed as useful pre-clinical models for therapeutic testing and high-throughput screening, as they can be bred in large numbers, are easy and inexpensive to maintain, are immunodeficient for up until 11 days post-fertilization and are, therefore, permissive to human cancer cells [66] [67] [68] . Using this model system, Eguiara et al. [65] found that breast cancer cell lines grown as tumorspheres formed masses and migrated to the tail at a higher frequency then cells grown as monolayers. While definitely not mainstream, the zebrafish model may provide a viable alternative for future large-scale studies that attempt to identify new therapeutic strategies specifically aimed at eradicating the CSC population. , researchers are now focusing their efforts on finding new therapies that will specifically target and eradicate this cell population. Despite these intensive efforts, CSC theory has been riddled with controversy. The in vivo models used to define these populations have several caveats including differences in frequency or readout of CSCs, discrepancies in the cell surface markers that select for CSCs, and variation in the number and phenotype of cell populations that display tumorigenic capacity. Furthermore, the relationship between CSCs and highly invasive or metastatic cells is still underdeveloped with few studies to date directly comparing these properties [41, 42, [69] [70] [71] [72] . In our laboratory, we have shown that medulloblastoma tumorspheres from cell lines exhibit downregulation of a cell motility transcription program in vitro [61] . It will be interesting to see whether highly malignant pediatric brain tumor cells in a ''stem cell state'' also display this same suppression of cell motility genes in vivo. An inverse correlation would suggest that drugs targeting cells in the migratory or invasive state will not abrogate the putative CSCs in a state of enhanced self-renewal. Furthermore, recent studies demonstrating interconversion between stem cell and more differentiated states raise more questions: Will one cell phenotype compensate for another following treatment, thereby negating the long-term benefit of cell-directed therapies? If CSCs are a ''moving target'', then how can we expect to tackle the daunting task of completely eradicating them? Our long-term goal is to identify novel therapeutic targets that will eliminate not only the cells responsible for tumor initiation and propagation but also the highly infiltrative cells that are the basis for recurrence.
Conclusions
Whether most or only a few cancers follow a CSC model remains an unanswered question. In vivo transplantation assays combined with more cell specific marking and fate mapping and advanced imaging technologies will be imperative for the future. Whether your system of choice is a ''humanized'' xenograft, a GEM or a zebrafish, we will continue to question whether these models can ever truly recapitulate the human tumor microenvironment? However, any cell population that displays the ability to initiate tumorigenesis, to maintain it, or to invade and/or metastasize in any model system should be carefully studied and dissected. As optimization of animal models continues, and our understanding of CSC theory evolves, our view of CSCs within a heterogeneous tumor environment will likely become even more complex. 
